<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04579419</url>
  </required_header>
  <id_info>
    <org_study_id>RC19/371</org_study_id>
    <nct_id>NCT04579419</nct_id>
  </id_info>
  <brief_title>Injection Site Pain Botulinum Toxin Reconstituted in NS With and Without Sodium Bicarbonate</brief_title>
  <official_title>Injection Site Pain, Onset and Duration of Action of Botulinum Toxin Reconstituted in Normal Saline With and Without Sodium Bicarbonate; A Prospective, Single Center, Randomized, Double-Blind Interventional Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King Abdulaziz Medical City</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King Abdulaziz Medical City</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to investigate the effects of botulinum toxin type A injections&#xD;
      diluted with the mixture of sodium bicarbonate (SB) and normal saline (NS) on pain reduction,&#xD;
      onset of action and duration of action.&#xD;
&#xD;
      This is a prospective, randomized, double-blind clinical study, which included 30 female&#xD;
      patients (age&gt;25). The patients were randomized to receive botulinum toxin (BT) injections&#xD;
      diluted with NS and SB on one side of the face and saline control injections on the other&#xD;
      side. Pain severity was assessed using visual analogue scale. The onset and duration of&#xD;
      action were recorded according to the patients' subjective opinions after 1 week and 3&#xD;
      months, respectively. The study was approved with an IRB (Institutional Review Board) number&#xD;
      of RC19/371.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 9, 2019</start_date>
  <completion_date type="Actual">August 9, 2020</completion_date>
  <primary_completion_date type="Actual">August 9, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Injection site pain</measure>
    <time_frame>Immediately after the injections</time_frame>
    <description>Pain severity was assessed using Visual Analogue Scale (VAS).The VAS score ranged from 0 to 10, with 0 representing no pain and 10 the greatest imaginable pain. Higher scores indicated worse outcome.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Wrinkle</condition>
  <arm_group>
    <arm_group_label>Sodium Bicarbonate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Bicarbonate</intervention_name>
    <description>Botulinum Toxin diluted in Sodium Bicarbonate</description>
    <arm_group_label>Sodium Bicarbonate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>0.9 NaCl</description>
    <arm_group_label>Normal Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any female patient who is in good health and has moderate dynamic forehead and&#xD;
             glabellar wrinkles.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  â€¢ Patients &lt;25 years old&#xD;
&#xD;
               -  Presence of neuromuscular disease or intake of drugs affecting muscle tone.&#xD;
&#xD;
               -  Any active infection in the treatment area.&#xD;
&#xD;
               -  Patients receiving anticoagulation or had a diagnosis of bleeding disorders.&#xD;
&#xD;
               -  Any patient who had undergone the following treatments to the forehead area in&#xD;
                  the past 6 months: botulinum toxin injections, ablative laser procedures,&#xD;
                  radiofrequency device treatments, ultrasound device treatments, or medium to deep&#xD;
                  chemical peels.&#xD;
&#xD;
               -  Any patient who had temporary soft-tissue augmentation material to the forehead&#xD;
                  area in the past 12 months, semi permanent soft-tissue augmentation material in&#xD;
                  the past 2 years, or permanent soft-tissue augmentation material at any point in&#xD;
                  the past.&#xD;
&#xD;
               -  Any patient with prior facial cosmetic surgical procedures such as eyebrow-lifts,&#xD;
                  blepharoplasties, and rhytidectomies.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>King Abdulaziz Medical City</name>
      <address>
        <city>Riyadh</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 28, 2020</study_first_submitted>
  <study_first_submitted_qc>October 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>October 2, 2020</last_update_submitted>
  <last_update_submitted_qc>October 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>King Abdulaziz Medical City</investigator_affiliation>
    <investigator_full_name>Leen Hijazi</investigator_full_name>
    <investigator_title>Medical Intern</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

